Literature DB >> 9535622

Sickle cell trait as a risk factor for secondary hemorrhage in children with traumatic hyphema.

A Nasrullah1, N C Kerr.   

Abstract

PURPOSE: To determine risk factors for secondary hemorrhage and poor visual outcome in children with traumatic hyphemas.
METHODS: We reviewed 99 eyes of 97 children younger than 18 years who had been hospitalized for hyphema within 48 hours of blunt eye trauma. Inpatient records were examined for race, age, sickle cell trait status, size of hyphema and intraocular pressure at admission, secondary hemorrhage (rebleed of hyphema), and medications while hospitalized. Fifty-five eyes of 53 children had at least 1 month of follow-up or attained best-corrected visual acuity of 20/50 or better at their last outpatient visit.
RESULTS: Among 99 eyes of 97 children with traumatic hyphema, secondary hemorrhage occurred in nine eyes (9%). Among 72 eyes of 70 African-American children, secondary hemorrhage occurred in nine eyes (14%), whereas in 27 eyes of 27 white children, there were no secondary hemorrhages. However, when the 14 eyes of 13 sickle cell trait-positive children were excluded from the African-American group, the 57 eyes of sickle cell trait-negative African-American and white children did not have any secondary hemorrhages. The sickle cell trait-positive group had secondary hemorrhages in nine of 14 eyes (64%), significantly (P < .005) different from the 0% rate in the 57 eyes of African-American sickle cell trait-negative and white children. The sickle cell trait-positive group also had higher intraocular pressure and permanent visual impairment.
CONCLUSION: Sickle cell trait is a significant risk factor for secondary hemorrhage, increased intraocular pressure, and permanent visual impairment in children who have traumatic hyphemas following blunt trauma.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9535622     DOI: 10.1016/s0002-9394(14)71127-4

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  8 in total

Review 1.  [Blunt ocular trauma. Part I: blunt anterior segment trauma].

Authors:  A Viestenz; M Küchle
Journal:  Ophthalmologe       Date:  2004-12       Impact factor: 1.059

2.  Clinical Characteristics and Outcomes of Hyphema in Patients with Sickle Cell Trait: 10-Year Experience at the Wilmer Eye Institute.

Authors:  Tahreem Mir; Mustafa Iftikhar; Natalie Seidel; Michelle Trang; Morton F Goldberg; Fasika A Woreta
Journal:  Clin Ophthalmol       Date:  2020-12-01

3.  Traumatic hyphema in an intercollegiate baseball player: a case report.

Authors:  V G Stilger; J M Alt; T W Robinson
Journal:  J Athl Train       Date:  1999-01       Impact factor: 2.860

4.  Clinical Outcomes Associated With Sickle Cell Trait: A Systematic Review.

Authors:  Rakhi P Naik; Kim Smith-Whitley; Kathryn L Hassell; Nkeiruka I Umeh; Mariane de Montalembert; Puneet Sahota; Carlton Haywood; Jean Jenkins; Michele A Lloyd-Puryear; Clinton H Joiner; Vence L Bonham; Gregory J Kato
Journal:  Ann Intern Med       Date:  2018-10-30       Impact factor: 25.391

5.  Global Current Practice Patterns for the Management of Hyphema.

Authors:  Sarah C Miller; Prajna Meeralakshmi; Michael J Fliotsos; Grant A Justin; Yoshihiro Yonekawa; Ariel Chen; Annette K Hoskin; Richard J Blanch; Kara M Cavuoto; Rebecca Low; Ximin Li; Matthew Gardiner; T Y Alvin Liu; Ankoor S Shah; James D Auran; Rupesh Agrawal; Fasika A Woreta
Journal:  Clin Ophthalmol       Date:  2022-09-26

6.  Management of Traumatic Hyphema and Prevention of Its Complications.

Authors:  Evan J Chen; Airaj Fasiuddin
Journal:  Cureus       Date:  2021-06-20

7.  Traumatic hyphaema: a report of 472 consecutive cases.

Authors:  Adeyinka O Ashaye
Journal:  BMC Ophthalmol       Date:  2008-11-26       Impact factor: 2.209

8.  The injection of air/oxygen bubble into the anterior chamber of rabbits as a treatment for hyphema in patients with sickle cell disease.

Authors:  Emre Ayintap; Uğurcan Keskin; Fariz Sadigov; Mesut Coskun; Nilufer Ilhan; Sedat Motor; Hilal Semiz; Nihan Parlakfikirer
Journal:  J Ophthalmol       Date:  2014-04-07       Impact factor: 1.909

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.